Save 20% on All Global Market Reports With Code ONLINE20 – Gain Insights Into Tariffs, Inflation, and Industry Trends
What Is the Growth Potential of the Meningococcal Vaccines Market in the Next Decade?
The meningococcal vaccines market size has grown strongly in recent years. It will grow from $3.89 billion in 2024 to $4.26 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to disease incidence, global travel trends, healthcare infrastructure, epidemic preparedness, health insurance coverage.
The meningococcal vaccines market size is expected to see strong growth in the next few years. It will grow to $6.05 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to emergence of new strains, increasing globalization, growing healthcare investments, health initiatives, changing regulatory landscape. Major trends in the forecast period include personalized vaccines, digital vaccination records, gene editing technologies, multi-valent vaccines, subscription-based vaccine models.
Claim your free report sample now:
What Are the Key Growth Factors Supporting the Meningococcal Vaccines Market Expansion?
An increase in healthcare spending is expected to propel the growth of the meningococcal vaccine market going forward. Healthcare refers to a residential care institution, nursing facility, intermediate care facility for people with mental illnesses, or intermediate care facility for people with mental retardation. The high expense of new vaccine generations compared to their predecessors has become a key factor in discussions about whether the benefits of the new vaccinations justify their prices. Assessing the complete social and economic advantages of vaccination is becoming an increasingly important area of investigation in the literature on valuing vaccination. For instance, in May 2022, according to an article published by the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, healthcare spending in the United States had risen by 9.7% to $4.1 trillion, or $12,530 per person. This pace of growth is significantly higher than 2019's (4.3%). Therefore, an increase in healthcare spending is driving the growth of the meningococcal vaccine market.
Which Segments Are Attracting Maximum Investment in the Meningococcal Vaccines Market?
The meningococcal vaccines market covered in this report is segmented –
1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine
2) By Serotype: Men Acwy, Men B/Bc, Men C
3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults
4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels
5) By End user: Hospitals, Research, Academic Institutes
Subsegments:
1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine
2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine
3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines
What Are the Significant Trends in the Meningococcal Vaccines Market Across Regions?
Major companies operating in the meningococcal vaccines market are developing new vaccines for the prevention of serogroups to increase their profitability in the market. Meningococcal vaccines are preventive measures designed to protect individuals against infections caused by specific serogroups of the bacteria Neisseria meningitidis. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company received approval from FDA for the vaccine PENBRAYA. PENBRAYA, with extensive serogroup coverage, is the most comprehensive U.S.-approved meningococcal vaccine, safeguarding against groups A, B, C, W, and Y. FDA approval is grounded in robust Phase 2 and 3 trial data, confirming non-inferior immunogenicity to Trumenba + Menveo across all serogroups, coupled with favorable safety. Pfizer's September 2022 announcement revealed positive outcomes from a Phase 3 trial, comparing PENBRAYA to existing licensed meningococcal vaccines in terms of safety, tolerability, and immunogenicity.
Which Major Companies Are Operating in the Meningococcal Vaccines Market?
Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.
Get the full meningococcal vaccines market report here:
How Is Regional Performance Expected to Affect Meningococcal Vaccines Market Growth?
North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment